HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo’s Consumer E-commerce Sales Jump 142% In US, Improve Pan-European Marketing Potential

Executive Summary

While e-commerce is about 8% of Perrigo’s total sales, it increased 142% for its Americas consumer business and by “the high 40s” for its European consumer business, which online sales could change from “a string of pearls, a lot of regional brands” to product lines that sell across multiple countries.

You may also be interested in...



US Q3 Consumer Health Earnings Preview: Helm Changes, Supply Challenges, Separation Plan

July-September results for sales of OTC drugs, supplements and personal care products will come with CEO leaving J&J and P&G, a new leader for Perrigo Americas, Bausch Health likely offering Bausch + Lomb separation details and a cloud of rising costs related to supplies.

Catalent Looks To Firm Up Soft-Format Product Manufacturing, Acquires Bettera For $1Bn

Catalent plans to purchase softgel manufacturer Bettera Brands and other portfolio companies from Highlander Partners to expand its consumer health technology platform and respond to consumer demand for soft forms, including gummies, soft chews and lozenges.

Perrigo Moves Closer To Exclusive Consumer Focus With UK Rx Generics Business Sale

Perrigo’s ambitions to become a consumer-focused company are a step closer after the firm announced an immediate sale of a ‘non-core’ asset.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS150655

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel